Telix Pharmaceuticals (TLX) Non-Current Deffered Revenue (2023 - 2024)

Telix Pharmaceuticals (TLX) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $2.2 million as the latest value for Q4 2024.

  • Quarterly Non-Current Deffered Revenue fell 72.84% to $2.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2024, down 72.84% year-over-year, with the annual reading at $2.0 million for FY2024, 75.53% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2024 was $2.2 million at Telix Pharmaceuticals, down from $7.9 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $7.9 million in Q4 2023, with the low at $2.2 million in Q4 2024.